4.8 Article

DNA methylation as a mediator of HLA-DRB1☆15:01 and a protective variant in multiple sclerosis

Journal

NATURE COMMUNICATIONS
Volume 9, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/s41467-018-04732-5

Keywords

-

Funding

  1. Swedish Research Council
  2. Swedish Association for Persons with Neurological Disabilities
  3. Swedish Brain Foundation
  4. Swedish MS Foundation
  5. Petrus and Augusta Hedlunds Foundation
  6. Swedish AFA Insurance
  7. Knut and Alice Wallenberg Foundation
  8. Stockholm County Council (ALF project)
  9. AstraZeneca (AstraZeneca-Science for Life Laboratory collaboration)
  10. NIH [DP1 ES022579]
  11. Margaretha af Ugglas Foundation
  12. EU [306000]
  13. National Natural Science Foundation [31471212]
  14. German research foundation
  15. German MS competence network
  16. the EU project MultipleMS
  17. German Ministry for Education and Research (BMBF) as part of the German Competence Network Multiple Sclerosis (KKNMS) [01GI0916, 01GI0917]
  18. Helmholtz Zentrum Munchen-German Research Center for Environmental Health - BMBF
  19. State of Bavaria
  20. Munich Center of Health Sciences (MC-Health)
  21. Ludwig-Maximilians-Universitat, as part of LMUinnovativ
  22. Heinz Nixdorf Foundation
  23. BMBF [01ER0816, 01ZZ9603, 01ZZ0103, 01ZZ0403, 03ZIK012, 0315540A]
  24. German Migraine and Headache Society (DMKG)
  25. Almirall
  26. AstraZeneca
  27. Berlin-Chemie
  28. Boehringer
  29. Boots Healthcare
  30. GlaxoSmithKline (GSK)
  31. Janssen-Cilag
  32. McNeil Pharma
  33. Merck Sharp Dohme (MSD)
  34. Pfizer
  35. Institute of Epidemiology and Social Medicine, University of Munster
  36. Ministry of Cultural Affairs
  37. Social Ministry of the Federal State of Mecklenburg-West Pomerania

Ask authors/readers for more resources

The human leukocyte antigen (HLA) haplotype DRB1(star)15:01 is the major risk factor for multiple sclerosis (MS). Here, we find that DRB1(star)15:01 is hypomethylated and predominantly expressed in monocytes among carriers of DRB1(star)15:01. A differentially methylated region (DMR) encompassing HLA-DRB1 exon 2 is particularly affected and displays methylation-sensitive regulatory properties in vitro. Causal inference and Mendelian randomization provide evidence that HLA variants mediate risk for MS via changes in the HLA-DRB1 DMR that modify HLA-DRB1 expression. Meta-analysis of 14,259 cases and 171,347 controls confirms that these variants confer risk from DRB1(star)15:01 and also identifies a protective variant (rs9267649, p < 3.32 x 10(-8), odds ratio = 0.86) after conditioning for all MS-associated variants in the region. rs9267649 is associated with increased DNA methylation at the HLA-DRB1 DMR and reduced expression of HLA-DRB1, suggesting a modulation of the DRB1(star)15:01 effect. Our integrative approach provides insights into the molecular mechanisms of MS susceptibility and suggests putative therapeutic strategies targeting a methylation-mediated regulation of the major risk gene.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available